This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2010 Feb;51(2):223-5.

doi: 10.1194/jlr.E004366. Epub 2009 Nov 25.

Prelamin A prenylation and the treatment of progeria

Howard J Worman¹

Affiliations

Affiliation

¹ Department of Medicine and Department of Pathology and Cell Biology, College of Physicians and Surgeons, Columbia University, New York, NY, USA. hjw14@columbia.edu

PMID: 19965579
PMCID: PMC2803225
DOI: 10.1194/jlr.E004366

Comment

Prelamin A prenylation and the treatment of progeria

Howard J Worman. J Lipid Res. 2010 Feb.

. 2010 Feb;51(2):223-5.

doi: 10.1194/jlr.E004366. Epub 2009 Nov 25.

Author

Howard J Worman¹

Affiliation

¹ Department of Medicine and Department of Pathology and Cell Biology, College of Physicians and Surgeons, Columbia University, New York, NY, USA. hjw14@columbia.edu

PMID: 19965579
PMCID: PMC2803225
DOI: 10.1194/jlr.E004366

No abstract available

PubMed Disclaimer

Figures

Fig. 1. — Fig. 1.
Posttranslational processing of wild-type prelamin A to lamin A (left) and generation of progerin in HGPS (right). See text for details. FT, protein fanesyltransferase; ICMT, isoprenylcysteine carboxyl methyltransferase.

See this image and copyright information in PMC

Comment on

Assessing the efficacy of protein farnesyltransferase inhibitors in mouse models of progeria.
Yang SH, Chang SY, Andres DA, Spielmann HP, Young SG, Fong LG. Yang SH, et al. J Lipid Res. 2010 Feb;51(2):400-5. doi: 10.1194/jlr.M002808. Epub 2009 Oct 26. J Lipid Res. 2010. PMID: 19965595 Free PMC article.

Similar articles

An encouraging progress report on the treatment of progeria and its implications for atherogenesis.
Oshima J, Hisama FM, Martin GM. Oshima J, et al. Circulation. 2014 Jul 1;130(1):4-6. doi: 10.1161/CIRCULATIONAHA.114.010648. Epub 2014 May 2. Circulation. 2014. PMID: 24795391 Free PMC article. No abstract available.
N6-isopentenyladenosine improves nuclear shape in fibroblasts from humans with progeroid syndromes by inhibiting the farnesylation of prelamin A.
Bifulco M, D'Alessandro A, Paladino S, Malfitano AM, Notarnicola M, Caruso MG, Laezza C. Bifulco M, et al. FEBS J. 2013 Dec;280(23):6223-32. doi: 10.1111/febs.12544. Epub 2013 Nov 18. FEBS J. 2013. PMID: 24112551
Investigating the purpose of prelamin A processing.
Davies BS, Coffinier C, Yang SH, Barnes RH 2nd, Jung HJ, Young SG, Fong LG. Davies BS, et al. Nucleus. 2011 Jan-Feb;2(1):4-9. doi: 10.4161/nucl.2.1.13723. Nucleus. 2011. PMID: 21647293 Free PMC article. Review.
Prelamin A farnesylation and progeroid syndromes.
Young SG, Meta M, Yang SH, Fong LG. Young SG, et al. J Biol Chem. 2006 Dec 29;281(52):39741-5. doi: 10.1074/jbc.R600033200. Epub 2006 Nov 7. J Biol Chem. 2006. PMID: 17090536 Review.
An accumulation of non-farnesylated prelamin A causes cardiomyopathy but not progeria.
Davies BS, Barnes RH 2nd, Tu Y, Ren S, Andres DA, Spielmann HP, Lammerding J, Wang Y, Young SG, Fong LG. Davies BS, et al. Hum Mol Genet. 2010 Jul 1;19(13):2682-94. doi: 10.1093/hmg/ddq158. Epub 2010 Apr 26. Hum Mol Genet. 2010. PMID: 20421363 Free PMC article.

See all similar articles

Cited by

Prenyltransferase Inhibitors: Treating Human Ailments from Cancer to Parasitic Infections.
Ochocki JD, Distefano MD. Ochocki JD, et al. Medchemcomm. 2013 Mar;4(3):476-492. doi: 10.1039/C2MD20299A. Medchemcomm. 2013. PMID: 25530833 Free PMC article.
Selective Gas-Phase Oxidation and Localization of Alkylated Cysteine Residues in Polypeptide Ions via Ion/Ion Chemistry.
Pilo AL, Zhao F, McLuckey SA. Pilo AL, et al. J Proteome Res. 2016 Sep 2;15(9):3139-46. doi: 10.1021/acs.jproteome.6b00266. Epub 2016 Aug 18. J Proteome Res. 2016. PMID: 27476698 Free PMC article.
Recent Advances on the Structure and Function of RNA Acetyltransferase Kre33/NAT10.
Sleiman S, Dragon F. Sleiman S, et al. Cells. 2019 Sep 5;8(9):1035. doi: 10.3390/cells8091035. Cells. 2019. PMID: 31491951 Free PMC article. Review.
High-Throughput Screen Detects Calcium Signaling Dysfunction in Hutchinson-Gilford Progeria Syndrome.
Fafián-Labora JA, Morente-López M, de Toro FJ, Arufe MC. Fafián-Labora JA, et al. Int J Mol Sci. 2021 Jul 7;22(14):7327. doi: 10.3390/ijms22147327. Int J Mol Sci. 2021. PMID: 34298947 Free PMC article.

References

1. Merideth M. A., Gordon L. B., Clauss S., Sachdev V., Smith A. C., Perry M. B., Brewer C. C., Zalewski C., Kim H. J., Solomon B., et al. 2008. Phenotype and course of Hutchinson-Gilford progeria syndrome. N. Engl. J. Med. 358: 592–604. - PMC - PubMed
1. Eriksson M., Brown W. T., Gordon L. B., Glynn M. W., Singer J., Scott L., Erdos M. R., Robbins C. M., Moses T. Y., Berglund P., et al. 2003. Recurrent de novo point mutations in lamin A cause Hutchinson-Gilford progeria syndrome. Nature. 423: 293–298. - PMC - PubMed
1. De Sandre-Giovannoli A., Bernard R., Cau P., Navarro C., Amiel J., Boccaccio I., Lyonnet S., Stewart C. L., Munnich A., Le Merrer M., et al. 2003. Lamin a truncation in Hutchinson-Gilford progeria. Science. 300: 2055. - PubMed
1. Worman H. J., Bonne G., et al. 2007. “Laminopathies”: a wide spectrum of human diseases. Exp. Cell Res. 313: 2121–2133. - PMC - PubMed
1. Lin F., Worman H. J., et al. 1993. Structural organization of the human gene encoding nuclear lamin A and nuclear lamin C. J. Biol. Chem. 268: 16321–16326. - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources